| ■ 영문 제목 : Global Human Vaccines Administered Orally Market Growth 2021-2026 | |
 | ■ 상품코드 : LPI-2201K00048 ■ 조사/발행회사 : LP Information ■ 발행일 : 2021년 12월 (※2025년 최신판이 있습니다. 문의 주세요.) ■ 페이지수 : 115 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의료, 제약 |
| Single User (1명 열람용) | USD3,660 ⇒환산￦5,124,000 | 견적의뢰/주문/질문 |
| Multi User (5명 열람용) | USD5,490 ⇒환산￦7,686,000 | 견적의뢰/주문/질문 |
| Corporate User (동일기업내 공유가능) | USD7,320 ⇒환산￦10,248,000 | 견적의뢰/구입/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| 본 조사보고서는 경구 투여용 인간용 백신의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아, 중동/아프리카, 이집트, 남아프리카, 터키, 중동GCC국 등), 시장동향, 판매/유통업자/고객 리스트, 시장예측 (2021년-2026년), 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) 등의 정보를 포함하고 있습니다. 또한, 주요지역의 종류별 시장규모 (로타바이러스 백신, 콜레라 백신, 경구 폴리오 백신)와 용도별 시장규모 (공공용, 개인용) 데이터도 수록되어 있습니다. - 조사 범위 - 경영자용 요약 - 기업별 경구 투여용 인간용 백신 시장 점유율 - 지역별 경구 투여용 인간용 백신 시장규모 - 주요지역의 종류별 시장규모 (로타바이러스 백신, 콜레라 백신, 경구 폴리오 백신) - 주요지역의 용도별 시장규모 (공공용, 개인용) - 미주의 경구 투여용 인간용 백신 시장규모 (미국, 캐나다, 멕시코, 브라질 등) - 아시아의 경구 투여용 인간용 백신 시장규모 (중국, 일본, 한국, 동남아시아, 인도 등) - 유럽의 경구 투여용 인간용 백신 시장규모 (독일, 프랑스, 영국, 이탈리아, 러시아 등) - 중동/아프리카의 경구 투여용 인간용 백신 시장규모 (이집트, 남아프리카, 터키, 중동GCC지역 등) - 시장의 성장요인, 과제, 동향 - 마케팅, 유통업자, 고객리스트 - 세계의 경구 투여용 인간용 백신 시장예측 (2021년-2026년) - 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological, EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals - 조사의 결과/결론 |
According to this latest study, the 2021 growth of Human Vaccines Administered Orally will have significant change from previous year. By the most conservative estimates of global Human Vaccines Administered Orally market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Human Vaccines Administered Orally market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Vaccines Administered Orally market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Public
Private
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
1 Scope of the Report 2 Executive Summary 3 Global Human Vaccines Administered Orally by Company 4 Human Vaccines Administered Orally by Region 5 Americas 6 APAC 7 Europe 8 Middle East & Africa 9 Market Drivers, Challenges and Trends 10 Marketing, Distributors and Customer 11 Global Human Vaccines Administered Orally Market Forecast 12 Key Players Analysis 13 Research Findings and Conclusion List of TablesTable 1. Human Vaccines Administered Orally Consumption CAGR by Region (2020-2026) & ($ Millions) Table 2. Major Players of Rotavirus Vaccine Table 3. Major Players of Cholera Vaccine Table 4. Major Players of Oral Polio Vaccine Table 5. Global Human Vaccines Administered Orally Sales by Type (2016-2021) & (K Units) Table 6. Global Human Vaccines Administered Orally Sales Market Share by Type (2016-2021) Table 7. Global Human Vaccines Administered Orally Revenue by Type (2016-2021) & ($ million) Table 8. Global Human Vaccines Administered Orally Revenue Market Share by Type (2016-2021) Table 9. Global Human Vaccines Administered Orally Sale Price by Type (2016-2021) Table 10. Global Human Vaccines Administered Orally Sales by Application (2016-2021) & (K Units) Table 11. Global Human Vaccines Administered Orally Sales Market Share by Application (2016-2021) Table 12. Global Human Vaccines Administered Orally Value by Application (2016-2021) Table 13. Global Human Vaccines Administered Orally Revenue Market Share by Application (2016-2021) Table 14. Global Human Vaccines Administered Orally Sale Price by Application (2016-2021) Table 15. Global Human Vaccines Administered Orally Sales by Company (2019-2021) & (K Units) Table 16. Global Human Vaccines Administered Orally Sales Market Share by Company (2019-2021) Table 17. Global Human Vaccines Administered Orally Revenue by Company (2019-2021) ($ Millions) Table 18. Global Human Vaccines Administered Orally Revenue Market Share by Company (2019-2021) Table 19. Global Human Vaccines Administered Orally Sale Price by Company (2019-2021) Table 20. Key Manufacturers Human Vaccines Administered Orally Producing Area Distribution and Sales Area Table 21. Players Human Vaccines Administered Orally Products Offered Table 22. Human Vaccines Administered Orally Concentration Ratio (CR3, CR5 and CR10) & (2019-2021) Table 23. New Products and Potential Entrants Table 24. Mergers & Acquisitions, Expansion Table 25. Global Human Vaccines Administered Orally Sales by Region (2016-2021) (K Units) Table 26. Global Human Vaccines Administered Orally Sales Market Share by Region (2016-2021) Table 27. Global Human Vaccines Administered Orally Revenue by Region (2016-2021) & ($ Millions) Table 28. Global Human Vaccines Administered Orally Revenue Market Share by Region (2016-2021) Table 29. Americas Human Vaccines Administered Orally Sales by Country (2016-2021) & (K Units) Table 30. Americas Human Vaccines Administered Orally Sales Market Share by Country (2016-2021) Table 31. Americas Human Vaccines Administered Orally Revenue by Country (2016-2021) & ($ Millions) Table 32. Americas Human Vaccines Administered Orally Revenue Market Share by Country (2016-2021) Table 33. Americas Human Vaccines Administered Orally Sales by Type (2016-2021) & (K Units) Table 34. Americas Human Vaccines Administered Orally Sales Market Share by Type (2016-2021) Table 35. Americas Human Vaccines Administered Orally Sales by Application (2016-2021) & (K Units) Table 36. Americas Human Vaccines Administered Orally Sales Market Share by Application (2016-2021) Table 37. APAC Human Vaccines Administered Orally Sales by Region (2016-2021) & (K Units) Table 38. APAC Human Vaccines Administered Orally Sales Market Share by Region (2016-2021) Table 39. APAC Human Vaccines Administered Orally Revenue by Region (2016-2021) & ($ Millions) Table 40. APAC Human Vaccines Administered Orally Revenue Market Share by Region (2016-2021) Table 41. APAC Human Vaccines Administered Orally Sales by Type (2016-2021) & (K Units) Table 42. APAC Human Vaccines Administered Orally Sales Market Share by Type (2016-2021) Table 43. APAC Human Vaccines Administered Orally Sales by Application (2016-2021) & (K Units) Table 44. APAC Human Vaccines Administered Orally Sales Market Share by Application (2016-2021) Table 45. Europe Human Vaccines Administered Orally Sales by Country (2016-2021) & (K Units) Table 46. Europe Human Vaccines Administered Orally Sales Market Share by Country (2016-2021) Table 47. Europe Human Vaccines Administered Orally Revenue by Country (2016-2021) & ($ Millions) Table 48. Europe Human Vaccines Administered Orally Revenue Market Share by Country (2016-2021) Table 49. Europe Human Vaccines Administered Orally Sales by Type (2016-2021) & (K Units) Table 50. Europe Human Vaccines Administered Orally Sales Market Share by Type (2016-2021) Table 51. Europe Human Vaccines Administered Orally Sales by Application (2016-2021) & (K Units) Table 52. Europe Human Vaccines Administered Orally Sales Market Share by Application (2016-2021) Table 53. Middle East & Africa Human Vaccines Administered Orally Sales by Country (2016-2021) & (K Units) Table 54. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country (2016-2021) Table 55. Middle East & Africa Human Vaccines Administered Orally Revenue by Country (2016-2021) & ($ Millions) Table 56. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country (2016-2021) Table 57. Middle East & Africa Human Vaccines Administered Orally Sales by Type (2016-2021) & (K Units) Table 58. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Type (2016-2021) Table 59. Middle East & Africa Human Vaccines Administered Orally Sales by Application (2016-2021) & (K Units) Table 60. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Application (2016-2021) Table 61. Key and Potential Regions of Human Vaccines Administered Orally Table 62. Key Application and Potential Industries of Human Vaccines Administered Orally Table 63. Key Challenges of Human Vaccines Administered Orally Table 64. Key Trends of Human Vaccines Administered Orally Table 65. Human Vaccines Administered Orally Distributors List Table 66. Human Vaccines Administered Orally Customer List Table 67. Global Human Vaccines Administered Orally Sales Forecast by Region (2021-2026) & (K Units) Table 68. Global Human Vaccines Administered Orally Consumption Market Forecast by Region Table 69. Global Human Vaccines Administered Orally Revenue Forecast by Region (2021-2026) & ($ millions) Table 70. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Region (2021-2026) Table 71. Americas Human Vaccines Administered Orally Sales Forecast by Country (2021-2026) & (K Units) Table 72. Americas Human Vaccines Administered Orally Revenue Forecast by Country (2021-2026) & ($ millions) Table 73. APAC Human Vaccines Administered Orally Sales Forecast by Region (2021-2026) & (K Units) Table 74. APAC Human Vaccines Administered Orally Revenue Forecast by Region (2021-2026) & ($ millions) Table 75. Europe Human Vaccines Administered Orally Sales Forecast by Country (2021-2026) & (K Units) Table 76. Europe Human Vaccines Administered Orally Revenue Forecast by Country (2021-2026) & ($ millions) Table 77. Middle East & Africa Human Vaccines Administered Orally Sales Forecast by Country (2021-2026) & (K Units) Table 78. Middle East & Africa Human Vaccines Administered Orally Revenue Forecast by Country (2021-2026) & ($ millions) Table 79. Global Human Vaccines Administered Orally Sales Forecast by Type (2021-2026) & (K Units) Table 80. Global Human Vaccines Administered Orally Sales Market Share Forecast by Type (2021-2026) Table 81. Global Human Vaccines Administered Orally Revenue Forecast by Type (2021-2026) & ($ Millions) Table 82. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Type (2021-2026) Table 83. Global Human Vaccines Administered Orally Sales Forecast by Application (2021-2026) & (K Units) Table 84. Global Human Vaccines Administered Orally Sales Market Share Forecast by Application (2021-2026) Table 85. Global Human Vaccines Administered Orally Revenue Forecast by Application (2021-2026) & ($ Millions) Table 86. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Application (2021-2026) Table 87. Merck Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 88. Merck Human Vaccines Administered Orally Product Offered Table 89. Merck Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 90. Merck Main Business Table 91. Merck Latest Developments Table 92. GSK Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 93. GSK Human Vaccines Administered Orally Product Offered Table 94. GSK Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 95. GSK Main Business Table 96. GSK Latest Developments Table 97. Sanofi Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 98. Sanofi Human Vaccines Administered Orally Product Offered Table 99. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 100. Sanofi Main Business Table 101. Sanofi Latest Developments Table 102. Lanzhou Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 103. Lanzhou Institute Human Vaccines Administered Orally Product Offered Table 104. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 105. Lanzhou Institute Main Business Table 106. Lanzhou Institute Latest Developments Table 107. Serum Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 108. Serum Institute Human Vaccines Administered Orally Product Offered Table 109. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 110. Serum Institute Main Business Table 111. Serum Institute Latest Developments Table 112. Valneva Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 113. Valneva Human Vaccines Administered Orally Product Offered Table 114. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 115. Valneva Main Business Table 116. Valneva Latest Developments Table 117. Shanghai United Cell Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 118. Shanghai United Cell Human Vaccines Administered Orally Product Offered Table 119. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 120. Shanghai United Cell Main Business Table 121. Shanghai United Cell Latest Developments Table 122. Bibcol Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 123. Bibcol Human Vaccines Administered Orally Product Offered Table 124. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 125. Bibcol Main Business Table 126. Bibcol Latest Developments Table 127. PaxVax Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 128. PaxVax Human Vaccines Administered Orally Product Offered Table 129. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 130. PaxVax Main Business Table 131. PaxVax Latest Developments Table 132. Vabiotech Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 133. Vabiotech Human Vaccines Administered Orally Product Offered Table 134. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 135. Vabiotech Main Business Table 136. Vabiotech Latest Developments Table 137. Tiantan Biological Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 138. Tiantan Biological Human Vaccines Administered Orally Product Offered Table 139. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 140. Tiantan Biological Main Business Table 141. Tiantan Biological Latest Developments Table 142. EuBiologics Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 143. EuBiologics Human Vaccines Administered Orally Product Offered Table 144. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 145. EuBiologics Main Business Table 146. EuBiologics Latest Developments Table 147. Panacea Biotec Ltd Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 148. Panacea Biotec Ltd Human Vaccines Administered Orally Product Offered Table 149. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 150. Panacea Biotec Ltd Main Business Table 151. Panacea Biotec Ltd Latest Developments Table 152. Bio-Med Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 153. Bio-Med Human Vaccines Administered Orally Product Offered Table 154. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 155. Bio-Med Main Business Table 156. Bio-Med Latest Developments Table 157. Halfkin Bio-Pharmaceuticals Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors Table 158. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Offered Table 159. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 160. Halfkin Bio-Pharmaceuticals Main Business Table 161. Halfkin Bio-Pharmaceuticals Latest Developments List of Figures Figure 1. Picture of Human Vaccines Administered Orally Figure 2. Human Vaccines Administered Orally Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Human Vaccines Administered Orally Sales Growth Rate 2016-2026 (K Units) Figure 7. Global Human Vaccines Administered Orally Revenue Growth Rate 2016-2026 ($ Millions) Figure 8. Human Vaccines Administered Orally Sales by Region (2021 & 2026) & ($ millions) Figure 9. Product Picture of Rotavirus Vaccine Figure 10. Product Picture of Cholera Vaccine Figure 11. Product Picture of Oral Polio Vaccine Figure 12. Global Human Vaccines Administered Orally Sales Market Share by Type in 2020 Figure 13. Global Human Vaccines Administered Orally Revenue Market Share by Type (2016-2021) Figure 14. Human Vaccines Administered Orally Consumed in Public Figure 15. Global Human Vaccines Administered Orally Market: Public (2016-2021) & (K Units) Figure 16. Human Vaccines Administered Orally Consumed in Private Figure 17. Global Human Vaccines Administered Orally Market: Private (2016-2021) & (K Units) Figure 18. Global Human Vaccines Administered Orally Sales Market Share by Application (2016-2021) Figure 19. Global Human Vaccines Administered Orally Revenue Market Share by Application in 2020 Figure 20. Human Vaccines Administered Orally Revenue Market by Company in 2020 ($ Million) Figure 21. Global Human Vaccines Administered Orally Revenue Market Share by Company in 2020 Figure 22. Global Human Vaccines Administered Orally Sales Market Share by Regions (2016-2021) Figure 23. Global Human Vaccines Administered Orally Revenue Market Share by Region in 2020 Figure 24. Americas Human Vaccines Administered Orally Sales 2016-2021 (K Units) Figure 25. Americas Human Vaccines Administered Orally Revenue 2016-2021 ($ Millions) Figure 26. APAC Human Vaccines Administered Orally Sales 2016-2021 (K Units) Figure 27. APAC Human Vaccines Administered Orally Revenue 2016-2021 ($ Millions) Figure 28. Europe Human Vaccines Administered Orally Sales 2016-2021 (K Units) Figure 29. Europe Human Vaccines Administered Orally Revenue 2016-2021 ($ Millions) Figure 30. Middle East & Africa Human Vaccines Administered Orally Sales 2016-2021 (K Units) Figure 31. Middle East & Africa Human Vaccines Administered Orally Revenue 2016-2021 ($ Millions) Figure 32. Americas Human Vaccines Administered Orally Sales Market Share by Country in 2020 Figure 33. Americas Human Vaccines Administered Orally Revenue Market Share by Country in 2020 Figure 34. Americas Human Vaccines Administered Orally Sales Market Share by Type in 2020 Figure 35. Americas Human Vaccines Administered Orally Sales Market Share by Application in 2020 Figure 36. United States Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 37. Canada Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 38. Mexico Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 39. Brazil Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 40. APAC Human Vaccines Administered Orally Sales Market Share by Region in 2020 Figure 41. APAC Human Vaccines Administered Orally Revenue Market Share by Regions in 2020 Figure 42. APAC Human Vaccines Administered Orally Sales Market Share by Type in 2020 Figure 43. APAC Human Vaccines Administered Orally Sales Market Share by Application in 2020 Figure 44. China Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 45. Japan Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 46. Korea Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 47. Southeast Asia Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 48. India Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 49. Australia Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 50. Europe Human Vaccines Administered Orally Sales Market Share by Country in 2020 Figure 51. Europe Human Vaccines Administered Orally Revenue Market Share by Country in 2020 Figure 52. Europe Human Vaccines Administered Orally Sales Market Share by Type in 2020 Figure 53. Europe Human Vaccines Administered Orally Sales Market Share by Application in 2020 Figure 54. Germany Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 55. France Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 56. UK Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 57. Italy Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 58. Russia Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 59. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country in 2020 Figure 60. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country in 2020 Figure 61. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Type in 2020 Figure 62. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Application in 2020 Figure 63. Egypt Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 64. South Africa Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 65. Israel Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 66. Turkey Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 67. GCC Country Human Vaccines Administered Orally Revenue Growth 2016-2021 ($ Millions) Figure 68. Channels of Distribution Figure 69. Distributors Profiles |
| ※본 조사보고서 [세계의 경구 투여용 인간용 백신 시장예측 2021년-2026년] (코드 : LPI-2201K00048) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 경구 투여용 인간용 백신 시장예측 2021년-2026년] 에 대해서 E메일 문의는 여기를 클릭하세요. |